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Abstract
Drug-induced neurotoxicity is a rare adverse reaction associated with ertapenem. Encephalopathy is a type of neurotoxicity
that is defined as a diffuse disease of the brain that alters brain function or structure. We report a patient with normal renal
function who developed ertapenem-induced encephalopathy manifesting as altered mental status, hallucinations, and dystonic
symptoms. The patient’s symptoms improved dramatically following ertapenem discontinuation, consistent with case reports
describing ertapenem neurotoxicity in renal dysfunction. Since clinical evidence strongly suggested ertapenem causality, we
utilized the Naranjo Scale to estimate the probability of an adverse drug reaction to ertapenem. Our patient received a
Naranjo Scale score of 7, suggesting a probable adverse drug reaction, with a reasonable temporal sequence to support our
conclusion.
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Introduction
Drug-induced neurotoxicity is a rare adverse reaction associated with carbapenem antibiotics.1-3 The data demonstrating a
neurotoxic association for carbapenems stems from animal
models, observational analyses, randomized controlled trials,
meta-analysis, and case reports.1-3,7-14 Imipenem is considered
to have the highest incidence of neurotoxicity among carbapenems, although there are published literature that refute this consensus.3,7,15-19 Encephalopathy is a type of neurotoxicity that is
defined as a diffuse disease of the brain that alters brain function or structure. Encephalopathy is characterized by an altered
mental state with additional symptoms including progressive
loss of memory and cognitive ability, personality changes,
myoclonus, nystagmus, tremor, and seizures. Carbapenem neurotoxicity is often evaluated and reported in terms of seizures,
and data on encephalopathy are limited. There are case reports
of ertapenem neurotoxic effects consisting of encephalopathy
in patients with end-stage renal disease or mild renal dysfunction. We report a patient with normal renal function who developed ertapenem-induced encephalopathy manifesting as
altered mental status, hallucinations, and dystonic symptoms.

Case Description
A 67-year-old male with a history of normal cognitive function was admitted with complaints of hallucinating for
approximately 1 week. Past medical history was significant

for chronic lumbar spine methicillin-sensitive Staphylococcus
aureus osteomyelitis maintained on life-long cephalexin
suppression (discontinued 2 weeks before presentation),
non-Hodgkin’s lymphoma in remission for 20 years, hypertension, atrial fibrillation, type 2 diabetes for 13 years (current HgA1C 8.2), ankylosing spondylitis, and esophagitis.
Table 1 lists the medication history at hospital admission.
The patient’s chronic lumbar spine osteomyelitis led to
numerous surgical manipulations of the spinal region, the
last of which was in 2012. The spine site became reinfected
in 2015 requiring hardware removal and multiple surgical
debridements. The spinal abscess wound cultures were positive for Enterobacter sp, Lactobacillus sp, and Candida glabrata. Treatment was initiated with oral fluconazole 600 mg
daily, piperacillin/tazobactam 4.5 g every 6 hours (changed
to ertapenem 1 g daily), and a wound vacuum-assisted closure dressing placed over the surgical site. Encephalopathic
symptoms including hallucinations began 5 days after
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Table 1. Medication History at Time of Admission.
Atorvastatin 80 mg daily
Cephalexin 500 mg every 12 hoursa
Diltiazem 120 mg daily
Ertapenem 1 g dailyb
Fluconazole 600 mg daily
Gabapentin 300 mg 3 times per day as needed
Glipizide 10 mg twice daily
Metformin 500 mg twice daily
Metoprolol tartrate 25 mg twice daily
Rivaroxaban 20 mg daily
a
Cephalexin was discontinued 2 weeks priors to presentation for altered
mental status.
b
Ertapenem was administered intravenously; all other medications were
orally administered.

repeated blood culture sets were negative. Urinalysis was
unremarkable. Arterial blood gas was noncontributory. Chest
radiograph revealed a left upper lobe pulmonary nodule but
subsequent thoracic computed tomography scan with contrast showed no contributing pathology and was stable.
Computed tomography of the head revealed no acute intracranial pathology. Electroencephalogram was also normal.
An extensive literature review of ertapenem, neurotoxicity,
and encephalopathy yielded case reports of ertapeneminduced central nervous system (CNS) events. Ertapenem
was stopped and ceftazidime 2 g every 8 hours was started.
His hallucinations and related neurological symptoms began
to improve and the patient recovered to his baseline mental
status within 2 days.

Discussion
Table 2. Summary of the Blood Test Results of Our Patient on
Admission.
Parameters
White cell count
Hemoglobin
Platelet
Sodium
Potassium
Blood urea nitrogen
Creatinine
Calcium
Albumin
Total bilirubin
Alkaline phosphatase
Alanine aminotransferase
Aspartate aminotransferase
Ammonia
Thyroid-stimulating hormone
Free T4

Readings
6.8
10.5
476
136
4.3
16
1.2a
9
2.2
0.3
107
102
76
29
5.93
0.95

Normal Ranges
3.6-11.1 K/mm3
12.9-16.1 g/dL
165-353 K/mm3
135-145 mmol/L
3.5-5.1 mmol/L
7-26 mg/dL
0.5-1.3 mg/dL
8.4-10.2 mg/dL
3.5-5.0 g/dL
0.2-1.2 mg/dL
40-150 U/L
0-55 U/L
5-34 U/L
18-72 Umol/L
0.35-4.94 µIU/mL
0.70-1.48 ng/dL

a
The serum creatinine ranged from 1.1 to 1.2 mg/dL over 2 years prior
to admission. The creatinine clearance calculation by the Cockcroft-Gault
method was 66 mL/min using adjusted body weight (actual body weight
92 kg; adjusted body weight 78 kg; ideal body weight 68 kg). Regardless
of the weight utilized (ideal, actual, or adjusted), the patients ertapenem
dose of 1 g daily is correct based off creatinine clearance dosing recommendations.19

ertapenem was started. Clinical examination at the bedside
revealed the patient to be responsive and alert but clearly
lethargic with clouded sensorium, lip smacking, mild
asterixis and tremor, and incoherent speech. Through the
entire hospitalization the patient remained afebrile with normal vital signs. Leukocyte count remained normal at an average of 5.5 × 109/L (6 readings). His renal function remained
stable and electrolytes were normal, as were random glucose
checks, thyroid function test, and ammonia level (Table 2).
Calculated creatinine clearance by the Cockcroft-Gault
equation was 66 mL/min on admission (Table 2). Urine and

Our report demonstrates a case of ertapenem-induced
encephalopathy manifesting as hallucinations and altered
mental status. The patient’s symptoms improved dramatically following ertapenem discontinuation, consistent with
case reports describing ertapenem neurotoxicity in renal
dysfunction. No other medication regimen changes were
done during the hospitalization, and no medical history was
identified as a cause of the encephalopathy. Since clinical
evidence strongly suggested ertapenem causality, we utilized the Naranjo Scale to estimate the probability of an
adverse drug reaction to ertapenem.20 Our patient received a
Naranjo Scale score of 7, suggesting a probable adverse
drug reaction, with a reasonable temporal sequence to support our conclusion (Table 3).
Imipenem has demonstrated the highest neurotoxic
adverse reaction rates among the carbapenems, while druginduced encephalopathy is rare with ertapenem and other
carbapenems. Imipenem neurotoxicity rates in adults range
from 0.4% to 10%, compared to less than 1% for meropenem, doripenem, and ertapenem.3 Specifically for ertapenem, postmarketing literature documenting ertapenem
neurotoxicity is scarce and limited to case reports with
patient-related factors (eg, renal dysfunction, history of central nervous system disorders).10,11,21-25 Published case reports
include the following:
•• Duquaine et al reported 2 patients who developed
unusual mental status changes while receiving ertapenem 1 g daily.21 One patient had acute renal dysfunction prior to starting therapy. Symptoms resolved on
drug discontinuation for both patients.
•• Wen et al reported 2 patients with advanced renal failure who received ertapenem at 500 mg daily and subsequently developed acute prolonged neurotoxicity.22
Baseline mental function returned 2 weeks after discontinuation of therapy for both patients.
•• Lee et al reported 4 patients on hemodialysis that developed unexplained central nervous system toxicity and
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Table 3. Naranjo Adverse Reaction Probability Scale.
Question

Yes

No

Do Not Know

Case Report Score

Are there previous conclusive reports about the reaction
Did the adverse event appear after the suspected drug was administered?
Did the adverse reaction improve when the drug was discontinued or a
specific antagonist was administered?
Did the adverse event reappear when the drug was re-administered?
Are there alternative causes (other than the drug) that could on their own
have caused the reaction?
Did the reaction reappear when a placebo was given?
Was the drug detected in blood (or other fluids) in concentrations known to
be toxic?
Was the reaction more severe when the dose was increased or less severe
when the dose was decreased?
Did the patient have a similar reaction to the same or similar drugs in any
previous exposure?
Was the adverse event confirmed by any objective evidence?
Total score = 7a

+1
+2
+1

0
−1

0

0
0
0

+1
+2
+1

+2
−1

−1
+2

0
0

0
+2

−1
+1

+1
0

0
0

0
0

+1

0

0

0

+1

0

0

0

+1

0

0

+1

a

Total score 5 to 8 = probable adverse drug reaction, with a reasonable temporal sequence to support the reaction.

hallucinations after receiving 500 mg.23 Discontinuing
the drug led to symptom resolution in all 4 patients.
•• Shea et al reported a patient with moderate renal
impairment who developed encephalopathy with
delayed recovery of 2 weeks. The patient exhibited a
full recovery after cessation of ertapenem.24
•• Oo et al reported 2 cases of ertapenem neurotoxicity,
including psychosis and encephalopathy.10 Symptoms
resolved within 3 and 10 days of discontinuing
ertapenem.
•• Kong et al reported a case of ertapenem-induced
visual hallucinations.11 Subsequent re-introduction of
ertapenem resulted in almost identical symptoms.
Complete resolution of symptoms occurred after discontinuation of ertapenem, as observed in our case
study.
Risk factors for carbapenem neurotoxic adverse reactions
include the following: (1) basicity strength of the C-2 amino
group for carbapenems; (2) accumulation in the CNS, specifically in cases of excessive dosage or impaired renal clearance; (3) patients with CNS disorders (eg, past medical
history of seizure disorder).5,25-27 Among these risk factors,
molecular structure is the most important compound-related
factor and renal insufficiency is the most important patientrelated factor predisposing to carbapenem neurotoxicity.
Pharmacokinetic-related factors may also influence the neurotoxic reactions related to ertapenem. Neurotoxicity risk
factors include the following:

neurotoxic mechanism is via interactions with the
γ-amino butyric acid receptor A (GABAA).8,9 This
interaction is through the side chain on the second
carbon atom (C-2) in the carbapenem nucleus. A carbapenem with a basic C-2 side chain increases the
binding to GABAA resulting in higher neurotoxic
activity in animal models. Because of a basic C-2
side chain, imipenem has a higher tendency to produce neurotoxic adverse reactions compared to
meropenem because of the less basic side C-2 side
chain of meropenem.1-3,6-9 Conversely, ertapenem
has an acidic carboxyl group at the C-2 position, is
expected to have the lowest binding to GABAA, and
subsequently is thought to have the lowest potential
for neurotoxic activity.
•• Patient related: Patient-related risk factors for carbapenem neurotoxicity include advanced age, history
of CNS disease, renal insufficiency, low body weight,
and concurrent use of drugs that are nephrotoxic or
that may lower the seizure threshold.4,5 Published literature demonstrates that renal dysfunction (end-stage
renal disease or mild renal dysfunction) is the primary
patient-related factor.
•• Pharmacokinetic related: There are pharmacokinetic
parameters of ertapenem that also could contribute to
the drug’s ability to affect the CNS. These factors
include a high volume of distribution, high lipophilicity, high protein binding, strong CNS penetration, and
metabolites that can also inhibit GABA receptors.8,9

•• Compound related: Carbapenems have discordant
rates of neurotoxic adverse reactions potentially
because of structural differences within side
chains.1-3,6-9 Available data demonstrate the probable

Our patient is unique because he had no baseline cerebrovascular disease or history of renal dysfunction. Characteristics
of our patient that may have contributed include his age (67),
low albumin levels, potential overestimation of his renal
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function, and prior cephalexin suppression. Ertapenem is
highly protein bound—up to 95% bound to albumin; thus, our
patient may have been exposed to excessive free drug as his
albumin was low. In addition, ertapenem is renally excreted,
up to 80%, requiring dosage adjustments for creatinine clearance of less than 30 mL/min. Our patient’s creatinine clearance could have been overestimated as serum creatinine
measurements are not as accurate in the elderly.28 The creatinine clearance calculation of 66 mL/min utilized the adjusted
body weight of the patient. Regardless of the weight utilized
(ideal, actual, or adjusted), the patients ertapenem dose of 1 g
daily is correct based off creatinine clearance dosing recommendations (Table 2). Furthermore, while there is no known
interaction between cephalexin and ertapenem, it is possible
that cephalexin suppression could have had an impact on this
case. However, the patient tolerated the cephalexin while
receiving and tolerated ceftazidime after developing the CNS
symptoms. Furthermore, cephalexin was discontinued 2
weeks prior to presentation; therefore, it is unlikely that cephalexin has a role in the symptoms.
Previous studies and reviews on carbapenem antibiotics
indicated that the high degree of neurotoxicity is not a class
phenomenon for carbapenems, and that there are carbapenems that have a lower degree of neurotoxicity. Therefore,
non-imipenem carbapenems are thought to be safely administered at high doses and are useful in the treatment of CNS
infections. While this may be true, non-imipenem carbapenems have demonstrated a neurotoxic potential, and our case
report demonstrates a carbapenem with an acidic carboxyl
group administered to a patient with no neurotoxic risk factors can still develop encephalopathy. Our case report aims to
add to the growing body of literature of ertapenem-induced
neurotoxicity with the goal of increasing education regarding
the potential for these neurotoxic effects.

Conclusion
We are sharing our experience of a patient with normal renal
function who developed neurotoxicity following standard dosing of ertapenem. The goal of this case report is to draw attention to the neurologic and encephalopathic potential of
ertapenem. Identifying ertapenem as a potential causative
agent of these conditions can spare unnecessary investigations
and health care expenditures. In our patient, supportive care
following discontinuation of ertapenem resulted in complete
resolution of his hallucinations and altered mental status.
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